The prevalence of bariatric surgery has increased dramatically over the last decade. Bariatric surgery leads to changes in gastrointestinal processes which ultimately affect oral drug bioavail ability. Due to sparse clinical data, a "bottom-up" approach using in vitro-in vivo extrapolation (IVIVE) in conjunction with systems pharmacology may be valuable in predicting trends in oral drug exposure post surgery.
data for cyclosporine and atorvastatin acid were incorporated into the model and simulations were run to mimic clinical investigations post bariatric surgery.
RESULTS: Simulated exposure to cyclosporine post surgery was reduced due to a lower fraction absorbed (fa) and the reduced peak plasma concentrations were consistent with the reported clinical observations. Simulated oral drug exposure of atorvastatin acid post Roux-en-Y gastric bypass surgery was also reflective of the observed data with indications of counteracting interplay between a reduced fa and increased fraction that escapes gut wall metabolism (FG). Observed exposure profiles with regards to t max of atorvastatin acid post biliopancreatic diversion with duodenal switch were not fully recovered by simulations.
CONCLUSION: Trends in oral drug bioavailability pre-to post-bariatric surgery seem to be highly dependent on drug specific parameters such as affinity to CYP3A, solubility, permeability and surgery specific systems alterations. The potential of a systems pharmacology physiologically-based pharmacokinetic modeling approach was demonstrated, allowing a framework for optimization of oral drug therapy post bariatric surgery. Inability to fully recover observed changes in t max in certain scenarios suggests that additional systems parameters, which are currently unknown, may play a vital role. 
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